San Diego, California, USA, August 8, 2026
Blacksmith Medicines has announced the publication of new research in the Journal of Medicinal Chemistry highlighting the discovery and optimization of novel non-hydroxamate LpxC inhibitors designed to combat multidrug-resistant Gram-negative bacterial infections. The peer-reviewed study demonstrates the potential of the company’s proprietary metalloenzyme-targeting drug discovery platform to develop differentiated small-molecule therapies against one of the most challenging classes of antibacterial targets. The research introduces an innovative approach that avoids traditional hydroxamic acid chemistry, which has historically limited the development of LpxC-targeted antibiotics because of poor drug-like properties. By utilizing a proprietary metal-binding pharmacophore library together with advanced computational drug design, Blacksmith has generated promising non-hydroxamate LpxC inhibitors, supporting the advancement of its lead antibacterial candidate, FG-2101, for both intravenous and oral treatment of susceptible and multidrug-resistant Gram-negative infections. The findings represent an important step toward addressing the growing global threat of antimicrobial resistance (AMR) through next-generation precision medicinal chemistry.
Novel LpxC Inhibitors Target Drug-Resistant Bacterial Infections
The published research focuses on LpxC, a zinc-dependent metalloenzyme that plays a critical role in the survival of Gram-negative bacteria while remaining absent from human cells and Gram-positive organisms, making it an attractive therapeutic target for antibiotic development. Although LpxC has been extensively studied for decades, previous drug discovery efforts have largely depended on hydroxamic acid-based inhibitors, many of which demonstrated suboptimal pharmacological characteristics that prevented successful clinical development. Blacksmith Medicines’ scientists have instead developed non-hydroxamate inhibitors capable of engaging the catalytic metal within the enzyme’s active site while potentially offering improved drug-like properties and differentiated safety profiles. According to the published study, these compounds demonstrated potent antibacterial activity and encouraging efficacy in preclinical animal models against multidrug-resistant Gram-negative pathogens, providing strong scientific support for continued development of this innovative therapeutic strategy.
Proprietary Platform Combines Chemistry and Computational Design
The success of the research is driven by Blacksmith Medicines’ proprietary metalloenzyme drug discovery platform, which integrates advanced medicinal chemistry, computational modeling, and structure-based drug design. Central to the platform is a proprietary library of metal-binding pharmacophores, specifically designed to precisely interact with metal ions located within enzyme active sites. The company also employs an extensive database mapping metalloenzyme biology, disease associations, and metal cofactors, together with metallo-CRISPR screening technologies and sophisticated computational docking tools that accelerate the identification and optimization of promising therapeutic candidates. This integrated approach enables researchers to overcome long-standing challenges associated with developing selective inhibitors against metal-dependent enzymes, which represent more than 30% of all known enzymes involved in essential biological processes. By combining computational precision with rational medicinal chemistry, the platform supports the rapid development of highly selective small-molecule therapeutics targeting diseases that have historically proven difficult to treat.
Advertisement
FG-2101 Strengthens Pipeline Against Antimicrobial Resistance
The publication also highlights progress for FG-2101, Blacksmith Medicines’ lead LpxC inhibitor currently advancing as both an intravenous and oral antibacterial therapy for multidrug-resistant Gram-negative infections. The program is supported through funding from the National Institute of Allergy and Infectious Diseases (NIAID) and previously received backing from CARB-X, reflecting the global importance of developing innovative antibiotics capable of addressing escalating antimicrobial resistance. As resistant bacterial infections continue to threaten public health worldwide, the development of next-generation metalloenzyme inhibitors offers a promising strategy for expanding the limited pipeline of novel antibacterial therapies. Blacksmith Medicines’ latest publication demonstrates how innovative bioinorganic chemistry, advanced computational drug discovery, and precision medicinal chemistry can generate differentiated antibiotic candidates with the potential to overcome limitations of previous approaches. The research further reinforces the company’s growing leadership in metalloenzyme-targeted therapeutics and its commitment to developing innovative medicines that address critical unmet medical needs in infectious diseases and beyond.
Source: Blacksmith Medicines press release
